Low uveitis rates with axial spondyloarthritis treated with bimekizumab

To cite: Brown MA, Rudwaleit M, van Gaalen FA, et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases Published Online First: 08 July 2024. doi: 10.1136/ard-2024-225933

Read the full article here: http://dx.doi.org/10.1136/ard-2024-22...

Objective: Acute anterior uveitis (‘uveitis’) is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis management. We report pooled analyses of uveitis incidence in patients receiving bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, from phase 2b/3 trials.
Conclusions: Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA.